FDA delays decision on GSK bone cancer drug acquired in $2B buyout
The FDA delayed its decision on GSK's momelotinib, a potential myelofibrosis treatment, to review new data, pushing the verdict to Sept. 16. GSK, confident in its application, aims for broader use approval. Despite competition from existing JAK inhibitors, momelotinib offers unique benefits, including anemia reduction, though Jakafi remains the preferred first-line treatment.
Reference News
The FDA delayed its decision on GSK's momelotinib, a potential myelofibrosis treatment, to review new data, pushing the verdict to Sept. 16. GSK, confident in its application, aims for broader use approval. Despite competition from existing JAK inhibitors, momelotinib offers unique benefits, including anemia reduction, though Jakafi remains the preferred first-line treatment.